FDA Grants Authorization to Treat COVID-19 Patients With Zofin

Organicell Regenerative Medicine, Inc. announced on September 2, 2020, that the U.S. FDA granted emergency, expanded access approval to treat two mild to moderate COVID-19 disease patients and one “Long-Hauler” post-COVID-19 patient with Zofin.

Zofin contains approximately 400 billion Extracellular Vesicles per milliliter quantified in every batch by Nanosight technology. Extracellular Vesicles are nanovesicles that contain protein and microRNA that can be transferred to other cells to support tissue repair and homeostasis, says the company.

George Shapiro, M.D., Chief Medical Officer of Organicell said in a press release, “The outpatients with different stages of COVID-19 were treated with Zofin with physicians for all patients reporting significant improvement.”